Thus, mutations in RBM10 are associated with tumor stage, lymph node metastasis, and poor survival rate, and therefore, there is potential in exploring the use of RBM10 as a biomarker for the progression and prognosis of LUAD. This evidence concerns the gene RBM10 and metastatic malignant neoplasm in the lymph nodes.